Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single-Arm, Single-Center Clinical Study Assessing the Safety and Efficacy of BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell Therapy in Multiple Refractory Autoimmune Diseases

NCT06794008 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06794008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single-Arm, Single-Center Clinical Study Assessing the Safety and Efficacy of BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell Therapy in Multiple Refractory Autoimmune Diseases
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 26, 2024
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired thrombotic thrombocytopenic purpura, anca-associated vasculitis, antiphospholipid syndrome, behcet disease, igg4-related diseases, inflammatory myopathy, sjogren syndrome, systemic lupus erythematosus, systemic sclerosis (ssc)